BIOTE CORP -A (BTMD) Fundamental Analysis & Valuation

NASDAQ:BTMD • US0906831039

Current stock price

2.22 USD
+0.12 (+5.71%)
At close:
2.22 USD
0 (0%)
After Hours:

This BTMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BTMD Profitability Analysis

1.1 Basic Checks

  • BTMD had positive earnings in the past year.
  • In the past year BTMD had a positive cash flow from operations.
  • BTMD had positive earnings in 4 of the past 5 years.
  • Of the past 5 years BTMD 4 years had a positive operating cash flow.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M -60M

1.2 Ratios

  • With an excellent Return On Assets value of 25.13%, BTMD belongs to the best of the industry, outperforming 98.43% of the companies in the same industry.
  • BTMD has a better Return On Invested Capital (44.85%) than 99.48% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BTMD is significantly above the industry average of 13.11%.
  • The 3 year average ROIC (32.37%) for BTMD is below the current ROIC(44.85%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 25.13%
ROE N/A
ROIC 44.85%
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • The Profit Margin of BTMD (14.07%) is better than 87.43% of its industry peers.
  • BTMD's Profit Margin has declined in the last couple of years.
  • With an excellent Operating Margin value of 18.50%, BTMD belongs to the best of the industry, outperforming 86.91% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BTMD has declined.
  • BTMD has a better Gross Margin (71.46%) than 78.53% of its industry peers.
  • In the last couple of years the Gross Margin of BTMD has grown nicely.
Industry RankSector Rank
OM 18.5%
PM (TTM) 14.07%
GM 71.46%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BTMD Health Analysis

2.1 Basic Checks

  • BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • BTMD has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BTMD has more shares outstanding
  • The debt/assets ratio for BTMD has been reduced compared to a year ago.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 2.64 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.64, BTMD is in the better half of the industry, outperforming 63.87% of the companies in the same industry.
  • BTMD has a debt to FCF ratio of 4.43. This is a neutral value as BTMD would need 4.43 years to pay back of all of its debts.
  • BTMD has a Debt to FCF ratio of 4.43. This is amongst the best in the industry. BTMD outperforms 84.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.43
Altman-Z 2.64
ROIC/WACC5.33
WACC8.42%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • BTMD has a Current Ratio of 1.22. This is a normal value and indicates that BTMD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.22, BTMD is doing worse than 81.15% of the companies in the same industry.
  • BTMD has a Quick Ratio of 1.22. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.79, BTMD is not doing good in the industry: 85.34% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.22
Quick Ratio 0.79
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BTMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 277.27% over the past year.
  • Measured over the past years, BTMD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -26.76% on average per year.
  • BTMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.22%.
  • Measured over the past years, BTMD shows a quite strong growth in Revenue. The Revenue has been growing by 10.51% on average per year.
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%

3.2 Future

  • BTMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.65% yearly.
  • Based on estimates for the next years, BTMD will show a quite strong growth in Revenue. The Revenue will grow by 8.86% on average per year.
EPS Next Y-63.75%
EPS Next 2Y-33.79%
EPS Next 3Y-8.66%
EPS Next 5Y9.65%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

8

4. BTMD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 2.67, which indicates a rather cheap valuation of BTMD.
  • BTMD's Price/Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 99.48% of the companies in the same industry.
  • BTMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.87.
  • With a Price/Forward Earnings ratio of 7.38, the valuation of BTMD can be described as very cheap.
  • BTMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 93.72% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 38.51. BTMD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 2.67
Fwd PE 7.38
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • BTMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BTMD is cheaper than 96.86% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BTMD is valued cheaply inside the industry as 98.95% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 3.08
EV/EBITDA 4.69
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The decent profitability rating of BTMD may justify a higher PE ratio.
  • BTMD's earnings are expected to decrease with -8.66% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.79%
EPS Next 3Y-8.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BTMD Dividend Analysis

5.1 Amount

  • BTMD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BTMD Fundamentals: All Metrics, Ratios and Statistics

BIOTE CORP -A

NASDAQ:BTMD (4/17/2026, 8:00:02 PM)

After market: 2.22 0 (0%)

2.22

+0.12 (+5.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11
Earnings (Next)05-12
Inst Owners63.53%
Inst Owner Change0.07%
Ins Owners9.77%
Ins Owner Change0%
Market Cap87.25M
Revenue(TTM)192.22M
Net Income(TTM)27.05M
Analysts81.82
Price Target3.24 (45.95%)
Short Float %5.5%
Short Ratio6.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)189.9%
Min EPS beat(2)17.65%
Max EPS beat(2)362.15%
EPS beat(4)4
Avg EPS beat(4)254.13%
Min EPS beat(4)17.65%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)90.98%
EPS beat(12)7
Avg EPS beat(12)15.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.53%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)-1.5%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.59%
Revenue beat(12)4
Avg Revenue beat(12)-1.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-34.47%
PT rev (3m)-37.68%
EPS NQ rev (1m)-13.64%
EPS NQ rev (3m)-13.64%
EPS NY rev (1m)18%
EPS NY rev (3m)14.93%
Revenue NQ rev (1m)-2.92%
Revenue NQ rev (3m)-3.12%
Revenue NY rev (1m)-2%
Revenue NY rev (3m)-2.41%
Valuation
Industry RankSector Rank
PE 2.67
Fwd PE 7.38
P/S 0.45
P/FCF 3.08
P/OCF 2.48
P/B N/A
P/tB N/A
EV/EBITDA 4.69
EPS(TTM)0.83
EY37.39%
EPS(NY)0.3
Fwd EY13.55%
FCF(TTM)0.72
FCFY32.47%
OCF(TTM)0.9
OCFY40.34%
SpS4.89
BVpS-1.49
TBVpS-1.86
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 25.13%
ROE N/A
ROCE 56.77%
ROIC 44.85%
ROICexc 72.95%
ROICexgc 117.64%
OM 18.5%
PM (TTM) 14.07%
GM 71.46%
FCFM 14.74%
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
ROICexc(3y)67.85%
ROICexc(5y)N/A
ROICexgc(3y)109.57%
ROICexgc(5y)N/A
ROCE(3y)40.97%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-44.74%
ROICexc growth 3YN/A
ROICexc growth 5Y-35.99%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
F-Score7
Asset Turnover1.79
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.43
Debt/EBITDA 2.57
Cap/Depr 187.03%
Cap/Sales 3.57%
Interest Coverage 4.51
Cash Conversion 89.73%
Profit Quality 104.75%
Current Ratio 1.22
Quick Ratio 0.79
Altman-Z 2.64
F-Score7
WACC8.42%
ROIC/WACC5.33
Cap/Depr(3y)157.42%
Cap/Depr(5y)165.61%
Cap/Sales(3y)2.85%
Cap/Sales(5y)2.48%
Profit Quality(3y)682.14%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
EPS Next Y-63.75%
EPS Next 2Y-33.79%
EPS Next 3Y-8.66%
EPS Next 5Y9.65%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%
EBIT growth 1Y-15.43%
EBIT growth 3YN/A
EBIT growth 5Y2.26%
EBIT Next Year14.18%
EBIT Next 3Y14.95%
EBIT Next 5Y17.45%
FCF growth 1Y-26.01%
FCF growth 3YN/A
FCF growth 5Y2.5%
OCF growth 1Y-22.21%
OCF growth 3YN/A
OCF growth 5Y5.89%

BIOTE CORP -A / BTMD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOTE CORP -A?

ChartMill assigns a fundamental rating of 6 / 10 to BTMD.


Can you provide the valuation status for BIOTE CORP -A?

ChartMill assigns a valuation rating of 8 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.


What is the profitability of BTMD stock?

BIOTE CORP -A (BTMD) has a profitability rating of 7 / 10.


What is the financial health of BIOTE CORP -A (BTMD) stock?

The financial health rating of BIOTE CORP -A (BTMD) is 5 / 10.


What is the earnings growth outlook for BIOTE CORP -A?

The Earnings per Share (EPS) of BIOTE CORP -A (BTMD) is expected to decline by -63.75% in the next year.